06th week of 2011 patent applcation highlights part 34 |
Patent application number | Title | Published |
20110033419 | Methods and Compositions for Treating Cancer - The invention relates to a method of treating cancer, comprising administering to a subject in need thereof an effective amount of a HSV-2 virus, wherein the virus lacks protein kinase activity of ICP10. The invention further relates to pharmaceutical compositions comprising HSV-2 virus, wherein the virus lacks protein kinase activity of ICP10. | 2011-02-10 |
20110033420 | MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 2011-02-10 |
20110033421 | METHODS RELATED TO IMMUNOSTIMULATORY NUCLEIC ACID-INDUCED INTERFERON - Methods and compositions are provided for extending the clinical utility of IFN-α in the treatment of a variety of viral and proliferative disorders. Among other aspects, the invention provides methods which increase the efficacy of IFN-α treatment and reduce IFN-α treatment-related side effects. In addition, methods are provided for supporting the survival and for activating natural interferon producing cells (IPCs) in vitro without exogenous IL-3 or GM-CSF. The invention is based on the discovery that certain CpG and non-CpG ISNAs promote survival and stimulation of IPCs. | 2011-02-10 |
20110033422 | TREATMENTS FOR FLAVIVIRIDAE VIRUS INFECTION - The present invention provides methods for treating infections, in a host, by viruses belonging to the Flaviviridae family, such as HCV, comprising administering an Ara-C homologue to the host. | 2011-02-10 |
20110033423 | PROBIOTICS FOR USE IN RELIEVING SYMPTOMS ASSOCIATED WITH GASTROINTESTINAL DISORDERS - The present invention provides probiotic compositions suitable for relieving symptoms associated with gastrointestinal disorders. In particular, the present invention provides compositions and methods to relieve symptoms associated with functional bowel disorders, irritable bowel syndrome, functional diarrhea, functional bloating, and other symptoms. | 2011-02-10 |
20110033424 | USE OF ADENOVIRUS AND NUCLEIC ACIDS CODING THEREFOR - The invention relates to the use of a virus, preferably an adenovirus, for producing a medicament. Said virus is replication-deficient in cells which do not contain YB-1 in the core and codes for an oncogene or oncogene product, especially an oncogene protein, which transactivates at least one viral gene, preferably an adenoviral gene, said gene being selected among the group comprising E1B55kDa, E4orf6, E4orf3, and E3ADP. | 2011-02-10 |
20110033425 | Parvovirus Having a CPG-Enriched Genome Useful for Cancer Therapy - A parvovirus characterized by a CpG-enriched genome, wherein the genome contains at least 2 additional CpG inserts that are not present in the wild type genome is described as well as the use of said parvovirus, e.g., a parvovirus based on parvovirus H1, LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus (RPV), Rat virus (RV), vectors based on the foregoing viral species, and/or cells capable of actively producing the foregoing viral species for the preparation of a pharmaceutical composition, e.g., for the treatment of cancer, preferably pancreas carcinoma, hepatoma or lymphoma. | 2011-02-10 |
20110033426 | USE OF MODIFIED CELLS FOR THE TREATMENT OF MULTIPLE SCLEROSIS - The present invention describes blood cells chemically coupled with immunodominant myelin peptides and their use in the treatment of Multiple Sclerosis. | 2011-02-10 |
20110033427 | Expansion Of Renewable Stem Cell Populations - Ex vivo and in vivo methods of expansion of renewable stem cells, expanded populations of renewable stem cells and their uses. | 2011-02-10 |
20110033428 | METHOD FOR ISOLATING SMOOTH MUSCLE STEM CELLS - This invention relates to a method for isolating smooth muscle stem cells derived from mammalian smooth muscle comprising bringing mammalian smooth muscle cells into contact with a fluorescence-labeled anti-CD45 antibody, anti-CD34 antibody, and anti-CD49f antibody, and isolating cells that would not bind to the anti-CD45 antibody but would bind to the anti-CD34 antibody and the anti-CD49f antibody. | 2011-02-10 |
20110033429 | Inducible Gene Expression - The invention relates to vector constructs for an HIV-specific gene therapy. The expression of transgenes is coupled with an infection of the cell with HIV while the transcription of the transgene is controlled by a transcription control region derived from HIV. In addition, the transgene is improved with regard to RNA stability and expression efficiency by modifying the nucleotide sequence. | 2011-02-10 |
20110033430 | METHODS FOR THE INDUCTION OF A CELL TO ENTER THE ISLET 1+ LINEAGE AND A METHOD FOR THE EXPANSION THEREOF - The present invention relates to methods for the induction and a cell to enter the Islet 1 | 2011-02-10 |
20110033431 | TYPE A2 BOTULINUM TOXIN PREPARATION - A pharmaceutical preparation for use in a patient who has a neutralizing antibody to a | 2011-02-10 |
20110033432 | Combinations of Biological Control Agents and Insecticides - Compositions are provided that improve overall plant vigor and yield by combining agriculturally effective amounts of at least one environmentally friendly biological control agent and at least one chemical insect control agent. A composition of the present invention is particularly effective in the presence of fungal species. Use of a composition of the present invention leads to an overall reduction in crop losses caused by fungi and this reduction is much greater than would have been expected from application of either component alone. Methods for utilizing compositions of the present invention are also provided. Further the compositions according to this invention display a synergistic insecticidal, nematicidal, acaricidal or fungicidal activity. | 2011-02-10 |
20110033433 | Combinations of Fungicidally Active Yeast and Fungicides - Compositions are provided that improve overall plant vigor and yield by combining agriculturally effective amounts of at least one environmentally friendly biological control agent and at least one chemical fungicide. A composition of the present invention is particularly effective in the presence of fungal species. Use of a composition of the present invention leads to an overall reduction in crop losses caused by fungi and this reduction is much greater than would have been expected from application of either component alone. Methods for utilizing compositions of the present invention are also provided. Further the compositions according to this invention display synergistic insecticidal and/or fungicidal activity. | 2011-02-10 |
20110033434 | CULTURED THREE-DIMENSIONAL TISSUES AND USES THEREOF - The present disclosure provides compositions of three dimensional tissue that can be administered into tissues and organs using minimally invasive methods. The three dimensional tissues elaborate a repertoire of growth factors that facilitate repair or regeneration of damaged tissues and organs. | 2011-02-10 |
20110033435 | Composition of activated CD4 cells - The composition of activated CD4 cells is derived from a healthy human donor. The composition from the healthy human donor is suspended in an infusion media and packaged in a vehicle for administration to a subject to treat disease. | 2011-02-10 |
20110033436 | STABLE AQUEOUS SPORE-CONTAINING FORMULATION - Stable aqueous spore-containing chemical formulations having a low to medium viscosity profile are provided. The formulations comprise at least one spore in a mixture of water and at least one water miscible solvent, optionally at least one surfactant, optionally at least one stabilizer such as a metal salt, optionally at least one biocide, optionally at least one buffer, and optionally at least one chemical insecticide or fungicide or a mixture thereof. The formulations are particularly suitable as a seed coating and foliar spray. Methods of preparation as well as methods of treating a plant are also provided. | 2011-02-10 |
20110033437 | Debridement Method Using Topical Nitric Oxide Donor Devices and Compositions - The present invention relates to methods for removal of dead tissue from wounds or skin using topical nitric oxide donor devices and/or compositions. In one embodiment, the present invention relates to a transdermal patch device that is designed to deliver nitric oxide. In another embodiment, the present invention relates to one or more devices and/or compositions that are designed to deliver nitric oxide and optionally one or more other compounds, where such devices/compositions include, without limitation, bandages, layered bandages, adhesive bandages, transdermal patches, creams, ointments, or a any combination of two or more thereof. | 2011-02-10 |
20110033438 | Method and pharmacological composition for the diagnosis and treatment of male - Pharmaceutical compositions for treating male sub-fertility that include an agent that causes a reduction in an effect of extracellular DNA on sperm cells, are provided. The agent may be, for example, an enzyme that degrades DNA such as DNase, a substance that blocks the interaction between cell free DNA and sperm cell surface receptors, a substance that binds to DNA, a substance that inhibits endogenous sperm cell DNase, a substance that inhibits a member of a signal transduction pathway mediated by DNA binding to sperm cell surface receptors, or an agent that stimulates production of an endogenous substance that causes a reduction in an antifertility effect of cell free DNA on sperm cells. Also provided are methods for treating male sub-fertility by administering the pharmaceutical composition to a subject in need thereof. Further provided are methods for determining a fertility status in a male subject, methods for assisted reproduction, methods for selecting an assisted reproduction technique (ART), and methods for selecting sperm cells in a sperm cell population for use in an assisted reproduction technique. | 2011-02-10 |
20110033439 | TARGETED ANTIMICROBIALS AND RELATED COMPOSITIONS, METHODS AND SYSTEMS - Targeted antimicrobials are described and related, compositions, methods and systems. | 2011-02-10 |
20110033440 | NOVEL PROCESS FOR SOLUBILIZING PROTEIN FROM A PROTEINACEOUS MATERIAL AND COMPOSITIONS THEREOF - The process for solubilizing proteinaceous material of the present invention includes subjecting the proteinaceous material to a sufficient amount of a basic solution to obtain a supernatant that has a basic pH and exposing the supernatant to the basic solution for a sufficient length of time and temperature for hydrolysis to occur. The process also includes cooling the mixture of the supernatant and proteinaceous material and optionally acidifying the mixture. This process may also include recovering the solubilized protein from the supernatant for use in various applications. Also provided herein is a composition of solubilized proteins from eggshell membrane obtained using processes of the present invention. | 2011-02-10 |
20110033441 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH - The present invention relates to salts, solvates and substoichiometric solvates of N-[3-[[[2-[(2,3-dihydro-2-oxo-1H-indo1-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]-2-pyridinyl]-N-methylmethanesulfonamide. The invention also provides pharmaceutical compositions comprising such complexes, as well as methods of treating abnormal cell growth by administering the complexes of the invention. | 2011-02-10 |
20110033442 | TARGETS, INCLUDING YAP1, FOR ANTIFUNGAL DRUG DISCOVERY AND THERAPY - The present invention is based on the discovery of a two organism model system that can be used to identify virulence factors. The system is also useful in the process of drug delivery. More specifically, we have established valid fungal infection in | 2011-02-10 |
20110033443 | Method for Increasing Bone Mass - The present invention features methods for promoting the differentiation of osteoblast bone forming cells to a mineralization phenotype and increasing bone mass using inhibitors of Brahma. Subjects benefiting from such treatment may have non-union fractures, osteopenia or osteoporosis, osteosarcoma, or a bone graft or bone fusion or orthopedic and dental implants, osteolytic bone disease, skeletal defects or deficiencies or periodontal disease. | 2011-02-10 |
20110033444 | Genetic variants in a hypertension susceptibility gene Stk39 and uses thereof - The present invention is drawn to diagnosis and treatment of essential hypertension. In this regard, the present invention discloses genetic variants in a hypertension susceptibility gene Stk39 and its use in the diagnosis and treatment of essential hypertension. | 2011-02-10 |
20110033445 | CARBOHYDRATE-CONTAINING PAN CANCER MARKER - The effective epitope of CA215, a known cancer marker and antigen, has been demonstrated to include a carbohydrate moiety of defined composition and to be non-reactive with anti-human IgG, IgA and IgM, although CA215 is an immunoglobulin heavy chain-like molecule. The defined epitope may be used to prepare immunogenic compositions for treatment and prevention of cancers in humans and may be optimized as to protocol and formulation in animal model systems. Improved protocols for diagnosis and treatment are also described. | 2011-02-10 |
20110033446 | Treatment of HIV-1-infected individuals to reduce risk of coronary artery disease and suppress virus replication - The present invention provides novel methods for treating and preventing coronary artery disease in HIV-1-infected individuals by interfering with Nef-mediated effect on ABCA1. The invention further provides novel methods for suppressing HIV infection by stimulating cholesterol efflux from cells by stimulating expression of ABCA1 in HIV-1-infected individuals. These methods take advantage of the finding that Nef, a regulatory protein of HIV-1, (1) diminishes expression of ATP-binding cassette transporter A1 (ABCA1), the main transporter of cholesterol from cells to extracellular acceptors; and (2) impairs cholesterol efflux from HIV-1-infected macrophages leading to cholesterol accumulation and formation of foam cells, which is a characteristic feature of atherosclerosis. | 2011-02-10 |
20110033447 | Methods for Treating Osteoarthritis Pain By Administering a Nerve Growth Factor Antagonist and Compositions Containing the Same - The invention concerns anti-NGF antibodies (such as anti-NGF antagonist antibodies), and polynucleotides encoding the same. The invention further concerns use of such antibodies and/or polynucleotides in the treatment and/or prevention of pain, including post-surgical pain, rheumatoid arthritis pain, and osteoarthritis pain. | 2011-02-10 |
20110033448 | Inhibitors of LL-37 Mediated Immune Reactivity to Self Nucleic Acids - Methods and compositions for treating disease are provided. More particularly, methods and compositions of inhibiting pathogenic interferon production are prevented, which may be useful in the treatment of various diseases. In other embodiments, therapeutic compounds and methods for the treatment of autoimmune diseases and chronic inflammatory diseases are provided. One such method is a method for inhibiting pathogenic interferon production or inhibiting activation of plasmacytoid dendritic cells or treating an autoimmune or chronic inflammatory disease, which comprises inhibiting one or more of LL-37 and hCAP18. | 2011-02-10 |
20110033449 | Human immune therapies using a CD27 agonist alone or in combination with other immune modulators - Methods of inducing T cell proliferation and expansion in vivo for treating conditions wherein antigen-specific T cell immune response are therapeutically desirable such as cancer, infection, inflammation, allergy and autoimmunity and for enhancing the efficacy of vaccines are provided. These methods comprise the administration of at least one CD27 agonist, preferably an agonistic CD27 antibody, alone or in association with another moiety such as immune stimulant or immune modulator such as an anti-CD40, OX-40, 4-IBB, or CTLA-4 antibody or an agent that depletes regulatory cells, or a cytokine. These mono and combination therapies may also optionally include the administration of a desired antigen such as a tumor antigen, an allergen, an autoantigen, or an antigen specific to an infectious agent or pathogen against which a T cell response (often CD8+) is desirably elicited. | 2011-02-10 |
20110033450 | Antibody Against Anthrax Toxins - The invention relates to an anti PA antibody, in which the variable region of the heavy chain has an amino acid sequence represented by SEQ ID N°1 and in which the variable sequence of the light chain has an amino acid sequence represented by SEQ ID N°2, that is modified in order to improve its affinity and its tolerance in human beings. | 2011-02-10 |
20110033451 | INTERLEUKIN-17F ANTIBODIES AND OTHER IL-17F SIGNALING ANTAGONISTS AND USES THEREFOR - The present invention provides isolated and purified polynucleotides and polypeptides related to the IL-17F signaling pathway. The invention also provides antibodies to IL-17F homodimers and IL-17A/IL-17F heterodimers, and methods of isolating and purifying members of the IL-17 family, including IL-17A/IL-17F heterodimers, from a natural source. The present invention also is directed to novel methods for diagnosing, prognosing, monitoring the progress of, and treating and/or preventing disorders related to IL-17F signaling, i.e., IL-17F-associated disorders, including, but not limited to, inflammatory disorders, such as autoimmune diseases (e.g., arthritis (including rheumatoid arthritis), psoriasis, systemic lupus erythematosus, and multiple sclerosis), respiratory diseases (e.g., COPD, cystic fibrosis, asthma, allergy), transplant rejection (including solid organ transplant rejection), and inflammatory bowel diseases or disorders (IBDs, e.g., ulcerative colitis, Crohn's disease). The present invention is further directed to novel therapeutics and therapeutic targets, and to methods of screening and assessing test compounds for the intervention (treatment) and prevention of disorders related to IL-17F signaling. | 2011-02-10 |
20110033452 | Anti-Glypican 3 Antibody Having Modified Sugar Chain - An anti-glypican 3 antibody with modified sugar chains, more specifically, an anti-glypican 3 antibody lacking fucose is provided. The anti-glypican 3 antibody with modified sugar chains of the present invention may be produced by a process comprising introducing a nucleic acid encoding an anti-glypican 3 antibody into host cells with reduced fucose addition capability, such as YB2/0 cells and cells lacking a fucose transporter. The anti-glypican 3 antibody with modified sugar chains of the present invention has a high level of cytotoxic activity and therefore is useful as a cell growth inhibitor such as an anticancer agent. | 2011-02-10 |
20110033453 | USE OF PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF EGFR DEPENDENT DISEASES OR DISEASES THAT HAVE ACQUIRED RESISTANCE TO AGENTS THAT TARGET EGFR FAMILY MEMBERS - The present invention relates to the use of compounds of formula (I) | 2011-02-10 |
20110033454 | Methods For Treating Diseases Using Antibodies to Aminophospolipids - Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases. | 2011-02-10 |
20110033455 | Methods For Inhibiting The Binding Of Endosialin To Ligands - The invention provides methods for inhibiting the interaction of endosialin with endosialin ligands. The inhibition is effectuated on the genetic level, by inhibiting endosialin gene expression, and on the protein level, by blocking the interaction of cell-surface expressed endosialin with ligands such as fibronectin and collagen. The invention provides methods for identifying inhibitors of the interaction of endosialin with endosialin ligands. Also provided are methods for inhibiting angiogenesis and neovascularization in vivo and in vitro. | 2011-02-10 |
20110033456 | METHODS OF THERAPY FOR B-CELL MALIGNANCIES USING ANTAGONIST ANTI-CD40 ANTIBODIES - Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity when the antibody binds a CD40 antigen on a normal human B cell, exhibits antagonist activity when the antibody binds a CD40 antigen on a malignant human B cell, and can exhibit antagonist activity when the antibody binds a CD40 antigen on a normal human B cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of malignant human B cells. | 2011-02-10 |
20110033457 | COMBINATION OF EPOTHILONE ANALOGS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES - Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders. | 2011-02-10 |
20110033458 | COMBINATIONS COMPRISING EPOTHILONES AND PHARMACEUTICAL USES THEREOF - The invention relates to a pharmaceutical combination which comprises (a) a HER-1 or a HER-2 antibody or (b) at least one antineoplastic agent selected from the group consisting of aromatase inhibitors, antiestrogens, topoisomerase I inhibitors, topoisomerase II inhibitors, microtubule active agents, protein kinase C inhibitors, anti-angiogenic compounds, gonadorelin agonists, anti-androgens, histone deacetylase inhibitors and S-adenosylmethionine decarboxylase inhibitors; and (c) an epothilone derivative of formula I | 2011-02-10 |
20110033459 | COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR - The present invention is directed to pharmaceutical compositions and methods of using combination therapies containing [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea, or a pharmaceutically acceptable salt thereof, for the treatment of thrombosis diseases. | 2011-02-10 |
20110033460 | ANTI-ErbB2 ANTIBODIES - Anti-ErbB2 antibodies are described which bind to an epitope in Domain 1 of ErbB2 and induce cell death via apoptosis. Various uses for these antibodies are also described. | 2011-02-10 |
20110033461 | Combination Therapy for the Treatment of Cancer - Compositions which act synergistically to inhibit the growth of cancer cells and methods of use thereof are disclosed. | 2011-02-10 |
20110033462 | HUMANIZED MONOCLONAL ANTIBODIES THAT SPECIFICALLY BIND AND/OR NEUTRALIZE JAPANESE ENCEPHALITIS VIRUS (JEV) AND THEIR USE - Disclosed herein are isolated humanized monoclonal antibodies that specifically bind Japanese encephalitis virus (JEV) with a binding affinity of about 1.0 nM or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. Methods of treating, preventing, and/or ameliorating JEV infection in a subject with JEV also are disclosed. Additionally, the antibodies can be used to detect JEV in a sample, and methods of diagnosing JEV infection, or confirming a diagnosis of JEV infection in a subject, are disclosed herein that utilize these antibodies. | 2011-02-10 |
20110033463 | APHERESIS, ADMINISTRATION OF AGENT, OR COMBINATION THEREOF - A device is configured to remove a target molecule from a bodily fluid of a subject and to deliver a therapeutic agent to the subject. Such a device may be used for treatment of a disease associated with amyloid beta accumulation in the subject. Agents selected from the group consisting of an ApoE-modulating agent; a RAGE inhibitor; a β-secretase 1 (BACE1) inhibitor; a γ-secretase inhibitor; a muscarinic receptor subtype 1 (M1) agonists; a growth factor; an enzyme capable of degrading amyloid beta; a mitochondrial antioxidant; insulin; and an inhibitor of tumor necrosis factor (TNF) may be administered directly to the central nervous system of a subject for treatment of a disease associated with amyloid beta accumulation. | 2011-02-10 |
20110033464 | IMMUNOGLOBULIN FUSION PROTEIN FORMULATIONS - The present invention provides compositions of Ig fusion proteins, especially compositions including an Ig fusion protein, a bulking agent, a disaccharide, a surfactant, and a buffer. In one aspect, these compositions are stable under long-term storage or at least one freeze/thaw cycle. The invention also provides methods of preparation of the Ig fusion protein compositions. In one aspect, compositions of the invention are lyophilized. In a further aspect, the compositions are lyophilized by a process that includes an annealing step. | 2011-02-10 |
20110033465 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS - The present invention provides compositions and methods for treating disorders of cholesterol and lipid metabolism by administration of an anti-PCSK9 antibody or a peptide inhibitor of PCSK9. | 2011-02-10 |
20110033466 | HUMAN TRANSCRIPTOMES - Global gene expression patterns have been characterized in normal and cancerous human cells using serial analysis of gene expression (SAGE). Cancer cell-specific, cell-type specific, and ubiquitously expressed genes have been identified. This information can be used to provide combinations of cell type- and cancer-specific gene probes, as well as methods of using these probes to identify particular cell types, screen for useful drugs, reduce cancer-specific gene expression, standardize gene expression, and restore function to a diseased cell or tissue. | 2011-02-10 |
20110033467 | COMPOSITIONS AND METHODS COMPRISING A LIGAND OF CHEMERINR - The present invention relates to a G-protein coupled receptor and a novel ligand therefor. The invention provides screening assays for the identification of candidate compounds which modulate the activity of the G-protein coupled receptor, as well as assays useful for the diagnosis and treatment of a disease or disorder related to the dysregulation of G-protein coupled receptor signaling. | 2011-02-10 |
20110033468 | Ophthalmic Drug Delivery System Containing Phospholipid and Cholesterol - An ophthalmic drug delivery system that contains phospholipid and cholesterol for prolonging drug lifetime in the eyes. | 2011-02-10 |
20110033469 | LEUKOTRIENE B4 BINDING SOLUBLE LIPOCALIN RECEPTOR FROM IXODES RICINUS - Leukotriene B4 binding polypeptide is obtained from | 2011-02-10 |
20110033470 | Human G-Protein Coupled Receptor - A human G-protein coupled receptor polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for identifying antagonists and agonists to such polypeptide. Antagonists and agonists may be used therapeutically to inhibit or stimulate the G-protein coupled receptor. Also disclosed are assays for detecting mutations in the nucleic acid sequence encoding the G-protein coupled receptor. | 2011-02-10 |
20110033471 | METHODS AND COMPOSITIONS FOR MODULATING TUMOR CELL ACTIVITY - Antibodies which target clusterin, a protein involved in the epithelial-to-mesenchymal transition of carcinoma cells, are identified and characterized. The antibodies may be used to modulate tumour cell activity through binding the clusterin. | 2011-02-10 |
20110033472 | Tumor Endothelial Marker 5-alpha Molecules and Uses Thereof - The present invention provides Tumor Endothelial Marker 5α (TEM5α) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing TEM5α polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, or prevention of diseases, disorders, and conditions associated with TEM5α polypeptides. | 2011-02-10 |
20110033473 | ANTI INFLUENZA ANTIBODIES AND USES THEREOF - Provided are antibodies comprising an antigen recognition domain capable of binding an MHC molecule being complexed with an influenza peptide wherein the antibody does not bind the MHC molecule in an absence of the complexed peptide and wherein the antibody does not bind the peptide in an absence of the MHC molecule. Also provided are methods of using same for diagnosing and treating influenza. | 2011-02-10 |
20110033474 | INHIBITION OF PLATELET AGGREGATION - The present invention provides methods and compositions for preventing platelet aggregation and for treating individuals suffering from conditions or undergoing procedures that may result in unwanted platelet aggregation. In particular the invention provides to methods and compositions for arterial vessel pacification. The methods are based on the administration of a therapeutically effective amount of a glycoprotein IIb/IIIa receptor antagonist, e.g., xemilofiban. The treatment may commence prior to a medical or surgical procedure or an outbreak of a condition, either of which results in the activation of platelets that may lead to thrombus formation, and may continue thereafter. | 2011-02-10 |
20110033475 | USE OF BETA-GLUCANS AGAINST BIOLOGICAL WARFARE WEAPONS AND PATHOGENS INCLUDING ANTHRAX - The present invention provides a means to broadly protect the military and the public from injury from biological warfare weapons, particularly infective agents such as anthrax. Beta (1,3)-glucans, particularly whole glucan particles, PGG-Glucan, and microparticulate glucan, provide general immune enhancement, thereby increasing the body's ability to defend against a wide variety of biological threats. Beta (1,3)-glucans have been shown to increase the resistance to infection by anthrax and other infectious organisms when administered before and after infection. The anti-infective mechanism of β(1,3)-glucan appears to involve stimulation of the innate immune system through increased cytokine release and CR3 receptor activation. Beta (1,3)-glucan is pharmaceutically stable, relatively compact, and can also be used without significant side effects. Beta (1,3)-glucan can also enhance the effectiveness of other medical countermeasures such as antibiotics, vaccines, and immune antibodies. | 2011-02-10 |
20110033476 | COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF INFLUENZA - The present invention provides novel human anti-influenza antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of influenza infection. | 2011-02-10 |
20110033477 | METHOD FOR DIAGNOSING AND TREATING CHRONIC PSYCHIATRIC ILLNESSES AND MARKERS AND TARGETS FOR SUCH METHODS - The invention relates to the use of special conformers of the DISC1 protein as a marker or target for chronic psychiatric illnesses, particularly schizophrenia, bipolar disorder, or depression. | 2011-02-10 |
20110033478 | CANINE THYMIC STROMAL LYMPHOPOIETIN PROTEIN AND USES THEREOF - The present invention discloses a canine TSLP protein and a nucleic acid that encodes that protein. Peptide fragments of the protein that comprise specific epitopes of the canine TSLP protein are also disclosed. The canine TSLP protein and related peptide fragments may be used as an antigen for immunological assays, as well as for vaccines that induce anti-TSLP antibodies. The present invention further discloses methods of making and using the canine TSLP gene, the canine TSLP protein, and the related peptide fragments. | 2011-02-10 |
20110033479 | PROTEINS EZRIN, SERPIN B5, PEROXIREDOXIN-2 AND HEAT SHOCK PROTEIN BETA-1 AS AUTOANTIGENS FOR PSORIASIS VULGARIS AND POSTSTREPTOCOCCAL DISEASES - The present invention relates to autoantigens selected from Ezrin, Serpin B5, Peroxiredoxin-2, heat shock protein β1, and/or peptides comprising at least 5 consecutive amino acid residues of one of these autoantigenic proteins having immunological activity, or fragments, variants, or epitopes thereof and/or mixtures of at least two of the proteins and/or peptides as diagnostic tool for the detection of streptococcal driven conditions or as therapeutical agent for the treatment of streptococcal driven conditions. | 2011-02-10 |
20110033480 | METHODS AND COMPOSITIONS INVOLVING NUCLEOTIDE REPEAT DISORDERS - The present invention concerns the methods and compositions involving nucleic acids with long repeat sequences. In some embodiments of the invention, there are methods for generating such a nucleic acid, and in other methods, there are methods for using such a nucleic acid to screen for candidate therapeutic compounds. Furthermore the present invention relates to methods of screening for Notch inhibitors and other substances that may be used to treat muscle loss and wasting. | 2011-02-10 |
20110033481 | PROSPECTIVE IDENTIFICATION AND CHARACTERIZATION OF BREAST CANCER STEM CELLS - A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. We have developed a xenograft model in which we have been able to establish tumors from primary tumors via injection of tumors in the mammary glad of severely immunodeficient mice. These xenograft assays have allowed us to do biological and molecular assays to characterize clonogenic solid tumor stem cells. We have also developed evidence that strongly implicates the Notch pathway, especially Notch 4, as playing a central pathway in carcinogenesis. This discovery is the basis for solid tumor stem cell compositions, methods for distinguishing functionally different populations of tumor cells, methods for using these tumor cell populations for studying the effects of therapeutic agents on tumor growth, and methods for identifying and testing novel anti-cancer therapies directed to solid tumor stem cells. | 2011-02-10 |
20110033482 | HER3 AS A DETERMINANT FOR THE PROGNOSIS OF MELANOMA - Disclosed are inhibitors of HER3 for the treatment of melanoma, in particular melanoma metastases and/or refractory melanoma, pharmaceutical compositions comprising such an inhibitor and a method for the diagnosis or prognosis of melanoma. | 2011-02-10 |
20110033483 | SINGLE-CHAIN MULTIVALENT BINDING PROTEINS WITH EFFECTOR FUNCTION - Multivalent binding peptides, including bi-specific binding peptides, having immunoglobulin effector function are provided, along with encoding nucleic acids, vectors and host cells as well as methods for making such peptides and methods for using such peptides to treat or prevent a variety of diseases, disorders or conditions, as well as to ameliorate at least one symptom associated with such a disease, disorder or condition. | 2011-02-10 |
20110033484 | LprG AS A CHAPERONE OF IMMUNE ADJUVANTS - An adjuvant combination that stimulates immune activation or response includes a hydrophobic immune adjuvant and a pathogen derived lipoprotein that chaperones the hydrophobic immune adjuvant to an immune receptor. | 2011-02-10 |
20110033485 | ANALOGUES OF GLYCOLIPIDS USEFUL AS IMMUNOADJUVANTS - The invention provides analogs of alpha-galactosyl ceramide that increase the immune response elicited by various antigens. It also provides methods of using such compounds to increase the effectiveness of vaccines. | 2011-02-10 |
20110033486 | GENE EXPRESSION MARKERS FOR CROHN'S DISEASE - The present invention relates to methods of gene expression profiling for inflammatory bowel disease pathogenesis, in which the differential expression in a test sample from a mammalian subject of one or more IBD markers relative to a control is determined, wherein the differential expression in the test sample is indicative of an IBD in the mammalian subject from which the test sample was obtained. | 2011-02-10 |
20110033487 | VACCINES AND DIAGNOSTICS FOR THE EHRLICHIOSES - The present invention concerns VLPT immunoreactive compositions for | 2011-02-10 |
20110033488 | AGENTS AND METHODS FOR TREATMENT OF ANXIETY DISORDERS - Peptides derived from CNS-specific antigens, altered peptide ligands (APL) analogues of said peptides, T cells activated by such peptides, poly-YE, and any combination of said agents are useful for prevention, treatment and/or alleviation of anxiety disorders, particularly post-traumatic stress disorder, and for restoring BDNF levels in the brain of an individual after reduction of BDNF expression induced by stress. | 2011-02-10 |
20110033489 | Circovirus sequences associated with piglet weight loss disease (PWD) - The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccine, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided. | 2011-02-10 |
20110033490 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND/OR TREATING INFLUENZA INFECTION - The present invention provides HA polypeptides (e.g., H1 HA polypeptides) that bind to umbrella-topology glycans, and reagents and methods relating thereto. The present invention provides binding agents that bind to HA polypeptides (e.g., H1 HA polypeptides), and reagents and methods relating thereto. The present invention provides interfering agents that inhibit the binding of HA polypeptides (e.g., H1 HA polypeptides) to HA receptors, and reagents and methods relating thereto. The present invention provides compositions and methods for treating, preventing, and/or diagnosing influenza infection utilizing HA polypeptides, HA polypeptide binding agents, HA polypeptide interfering agents, and/or vaccine compositions comprising any of the foregoing. | 2011-02-10 |
20110033491 | MULTICOMPONENT MENINGOCOCCAL VACCINE - A composition is provided comprising | 2011-02-10 |
20110033492 | VACCINES FOR BRUCELLOSIS - A polypeptide selected from the group consisting of BMEII0923, BMEI0411, a protective fragment of BMEII0923 and BMEI0411 and immunologically active variants of BMEII0923 and BMEIO411, which provides a protective immune response against | 2011-02-10 |
20110033493 | VACCINE - The present invention provides a method of immunising a subject comprising the step of administering a composition comprising an antigen and a carbohydrate polymer comprising mannose to a mucosal site of the subject, methods of use of the composition for vaccination and sterilization and use of the composition in manufacturing a medicament. | 2011-02-10 |
20110033494 | Anti-Infective Agents and Uses Thereof - The present invention is concerned with novel immunostimulant microparticle compositions and their use as anti-infective agents in the treatment of bacterial and viral infections. | 2011-02-10 |
20110033495 | METHODS AND COMPOSITIONS FOR REDUCING THE IMPACT OF ENTERIC DISEASES - The present invention relates to the use of an immunogenic composition that comprises a PCV2 antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with an enteric infection, even more preferably, with enteric disease. The use relates to a method comprising the steps of administering the composition to an animal in need thereof, preferably prior to disease exposure. Administration of PCV2 antigen, preferably ORF2 of PCV2, lessens the incidence and reduces the severity of the enteric disease. | 2011-02-10 |
20110033496 | VACCINE FOR PROTECTION AGAINST LAWSONIA INTRACELLULARS - The present invention pertains to the use of a non-live carbohydrate containing composition, the carbohydrate being also found in live | 2011-02-10 |
20110033497 | VACCINE FOR PROTECTION AGAINST LAWSONIA INTRACELLULARIS, MYCOPLASMA HYOPNEUMONIAE AND PORCINE CIRCO VIRUS - The present invention pertains to a vaccine comprising in combination non-live antigens of | 2011-02-10 |
20110033498 | METHODS OF PREVENTING AND TREATING VIRAL INFECTIONS BY INHIBITING THE DelSGYLATION ACTIVITY OF OTU DOMAIN-CONTAINING VIRAL PROTEINS - Viruses having an impaired ability to deISGylate ISG15 conjugates, in particular, viral mutants comprising a mutation in the viral genome that reduces or eliminates the ability of the viral OTU domain-containing protein encoded by the viral genome to deISGylate ISG15 conjugates and/or deubiquitinate ubiquitinated proteins and/or deNeddylate Neddylated proteins are disclosed. Such viral mutants may be used in the formulation of immunogenic compositions for inducing an immune response and preventing, managing and/or treating a viral infection. Also disclosed are methods for identifying anti-viral compounds, in particular, methods of identifying compounds that reduce or inhibit the deISGylation activity and/or deubiquitination and/or deNeddylation activity of a viral OTU domain-containing protein. The compounds identified using such methods may be used as antiviral agents for the prevention, treatment and/or management of viral infections. | 2011-02-10 |
20110033499 | ANTI-VIRAL NUTRACEUTICAL - A method for the prophylaxis or treatment of a viral infection in a mammal is described. The method comprises administering to the mammal an effective amount of a mollusc hemocyanin and/or an active fragment thereof. The hemocyanin may be an abalone hemocyanin. | 2011-02-10 |
20110033500 | VACCINE COMPOSITIONS COMPRISING L2 AND/OR L3 IMMUNOTYPE LIPOOLIGOSACCHARIDES FROM LGTB-NEISSERIA MENINGITIDIS - The present invention relates to the field of neisserial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to processes of making novel engineered meningococcal strains which are more suitable for the production of neisserial, in particular meningococcal, outer-membrane vesicle (or bleb) vaccines. Advantageous processes and vaccine products are also described based on the use of novel LOS subunit or meningococcal outer-membrane vesicle (or bleb) vaccines which have been rendered safer and/or more effective for use in human subjects. In particular combinations of gene downregulations are described such as PorA and OpA, PorA and OpC, OpA and OpC, and PorA and OpA and OpC. Alternatively, or in addition, lgtB | 2011-02-10 |
20110033501 | RECOMBINANT BACTERIUM CAPABLE OF ELICITING AN IMMUNE RESPONSE AGAINST ENTERIC PATHOGENS - The present invention relates to a recombinant bacterium that is capable of eliciting an immune response against at least two enteric pathogens, without substantially inducing an immune response specific to the serotype of the bacterium. The invention also relates to methods of making such a bacterium and vaccines and methods of using such a bacterium. | 2011-02-10 |
20110033502 | LIVE GENETICALLY ATTENUATED MALARIA VACCINE - Method for inoculating a vertebrate host against malaria, by administering to the host a live | 2011-02-10 |
20110033503 | DRESSING COMPOSITIONS AND METHODS - Described is a spray-on hydrogel comprising water-soluble PEG polymers that cross-link in situ to form a hydrogel such that the cross-links are reversible. The hydrogel can be useful as a drug delivery composition, wound dressing or surgery adjuvant. Polyethylene glycol polymer and cross-linker solutions are sprayed simultaneously through a common orifice. Cross-linking via formation of thioether or disulfide bonds is initiated upon mixing, providing rapid gelation. The hydrogel components can be derivatized with RGD peptides or analogs thereof to promote retention in/on a body compartment such as the skin, surface of the eye, or a mucosa such as the vaginal mucosa. The cross-links are reversed using a reducing solution enabling easy removal of the hydrogel by dissolution. Processes for preparation of the cross-linker, RGD derivatized PEG and RGD-linked agents are also disclosed. | 2011-02-10 |
20110033504 | ARTICLES AND METHODS FOR REPAIRING DAMAGED NERVOUS TISSUE - The invention concerns substrates comprising a biocompatible gel and at least one of a plurality of cells, said cells being capable of producing at least one therapeutic agent. Other aspects of the invention concern methods of making such substrates and methods of repairing and regenerating damaged nervous tissue with the substrates. | 2011-02-10 |
20110033505 | METHODS AND COMPOSITIONS FOR TREATMENT OF ION IMBALANCES - The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising sodium-binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, chronic renal insufficiency, fluid overload, or sodium overload. | 2011-02-10 |
20110033506 | COMBINATION DOSAGE FORM OF LOW-DOSE MODAFINIL AND LOW-DOSE SILDENAFIL - Modified release formulations comprising at least one of modafinil and sildenafil, and combinations thereof, and a time-controlled delivery system coating. | 2011-02-10 |
20110033507 | Polypeptides KXK and Their Use - The invention concerns polypeptides of the general formula (I): A-(Xaa) | 2011-02-10 |
20110033508 | INJECTABLE MICROSPHERES FOR DERMAL AUGMENTATION AND TISSUE BULKING - The present invention relates to elastic, hydrophilic and substantially spherical microspheres useful for dermal augmentation and tissue bulking. The invention provides injectable compositions comprising the microspheres and a biocompatible carrier for use in dermal augmentation. The present invention further provides methods of dermal augmentation and tissue bulking, particularly for the treatment of skin contour deficiencies, Gastro-esophageal reflux disease, urinary incontinence, and urinary reflux disease, using the injectable compositions. | 2011-02-10 |
20110033509 | Cosmetic or dermatological article comprising a medium that is soluble in water - The present invention relates to a cosmetic or dermatological article comprising:
| 2011-02-10 |
20110033510 | COSMETIC COMPOSITION COMPRISING A COLORANT AND METHOD OF COSMETIC TREATMENT - The present invention relates to a cosmetic composition comprising, in a cosmetically acceptable medium, a colorant comprising an inorganic fibrous matrix with tunnels and organic dye compounds incorporated at least partially in said tunnels, said compounds being selected from the indigoids, and present in an amount such that the weight ratio of colorant to matrix is greater than or equal to 0.028. | 2011-02-10 |
20110033511 | COMPOSITE PARTICLES FOR USE IN ORAL HYGIENE - The present invention relates to functional composite particles for the oral care sector, more particularly for toothpastes and mouthwashes, which are charged with active ingredients which ensure a long-term antimicrobial or antibacterial effect in the oral cavity and hence reduce the formation of plaque and halitosis. The invention further relates to a process for producing these composite particles and also to their use for producing oral hygiene articles. | 2011-02-10 |
20110033512 | PERSONAL CARE COMPOSITION WITH IMPROVED SPREADABILITY - A stable personal care composition in the form of a substantially anhydrous oil matrix having improved spreadability that may comprise a hydrocarbon wax, a polar oil, and a non-emulsifying silicone elastomer. The weight ratio of the hydrocarbon wax to the polar oil is from about 0.01 to about 0.5. The personal care composition may exhibit a spreadability of 1.0 kg to about 5.0 kg and a hardness of about 3 g to about 120 g | 2011-02-10 |
20110033513 | Encapsulated Active Material Containing Nanoscaled Material - The present invention is directed to novel capsules containing active material and nanoscaled material and to methods for making capsules with enhanced performance and stability. The capsules are well suited for use in personal care applications, laundry products and perfume and fragrance products. | 2011-02-10 |
20110033514 | Semiochemical emission device - The present invention is directed to a chemical lure, comprising an enclosed container having a top, the top having one or more orifices; a gel matrix contained within the container, the matrix comprising a active ingredient and a carrier; and a headspace between the gel matrix and the top. The emission rate of the active ingredient from the orifices allows the invention to emit volatilized active ingredient for about 60 days. | 2011-02-10 |
20110033515 | TISSUE CONTACTING MATERIAL - A tissue contacting material comprising a plurality of regions comprising an outer region serving as a protective barrier, one or more inner regions, and a tissue contacting region. The plurality of regions each comprise one or more of a plurality of polymers selected from the group consisting of a first polymer comprising a crosslinked hydrophilic polymer and a second crosslinked polymeric matrix, formed of a crosslinkable polymer adapted to incorporate the first polymer without substantially reacting or crosslinking with the first polymer. The first and/or second polymers provide the respective regions with one or more properties including swellability in the presence of water, active agent content, permeability to the diffusion of active agent from or through the layer, moisture vapor permeability, and adhesion to tissue. | 2011-02-10 |
20110033516 | METHODS AND COMPOSITIONS FOR BONE HEALING BY PERIOSTIN - The present invention provides methods and compositions for increasing bone production and/or decreasing bone fracture healing time in a subject, by administering an effective amount of periostin and/or active peptides and/or fragments thereof. | 2011-02-10 |
20110033517 | COATINGS FOR IMPLANTABLE MEDICAL DEVICES COMPRISING HYDROPHILIC SUBSTANCES AND METHODS FOR FABRICATING THE SAME - A segmented polyurethane and an amphiphilic random or block copolymer are disclosed. The segmented polyurethane and the amphiphilic random or block copolymer can be used for fabricating a coating for an implantable medical device such as a stent. | 2011-02-10 |
20110033518 | PEPTIDES PROMOTING LIPID EFFLUX VIA ABCA1 AND ACTIVATING A LIPOPROTEIN LIPASE - Disclosed herein are peptides and peptide analogs with multiple amphipathic α-helical domains that promote lipid efflux from cells via an ABCA1-dependent pathway, as well as peptides that activate lipoprotein lipase, and compositions comprising such peptides or combinations thereof. Also provided herein are methods of using multi-domain amphipathic α-helical peptides or peptide analogs to treat or inhibit dyslipidemic disorders. Methods for identifying non-cytotoxic peptides that promote ABCA1-dependent lipid efflux from cells and activate lipoprotein lipase within cells are also disclosed herein. | 2011-02-10 |